Patterns of Care in Hormone-receptor Positive, Advanced Breast Cancer
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The purpose of this study is to characterize the current patterns of care for patients with hormone-receptor-positive, advanced breast cancer who have failed one prior endocrine therapy in Brazil. To investigate patient-related, disease-related and physician-related characteristics that correlate with the use of either endocrine treatment or chemotherapy in such patients. And to evaluate patients' understanding of the treatment options and their participation in the choice.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Primary care clinic
Histological or cytological diagnosis of breast cancer
Postmenopausal status at the time of enrolment, according to the following definitions:
History of bilateral oophorectomy at any age
Proven hormonal menopause
Positive estrogen receptor (ER) and/or progesterone receptor (PR) by immuno
Failure of one previous endocrine therapy in the adjuvant or metastatic setting
Use of no more than one previous chemotherapy regimen in the neoadjuvant or adjuvant setting
Indication to receive chemotherapy or endocrine therapy
Inability to comply with the study protocol
Use of more than one previous endocrine therapy, regardless of the setting; -- Previous use of chemotherapy for metastatic disease
Use of neoadjuvant endocrine therapy as the only previous type of endocrine therapy
Serious medical, surgical or psychiatric comorbidity that, upon investigator's discretion, should preclude participation in the study.